SCHEMBL7560095

SCHEMBL7560095

CC(=O)N[C@@H](Cc1ccc(OC(=O)[C@@H](N)CC(C)C)cc1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 2/20 0.55
ITGA2B P08514 2/20 0.55
LTA4H P09960 1/20 0.49
FOLH1 Q04609 1/20 0.49
LMNA P02545 1/20 0.46
ACE P12821 2/20 0.46
ALDH1A1 P00352 1/20 0.46
MME P08473 1/20 0.46
CPA1 P15085 1/20 0.46
ACE2 Q9BYF1 1/20 0.46
MMP2 P08253 2/20 0.44
MMP9 P14780 2/20 0.44
MMP7 P09237 1/20 0.44
MMP12 P39900 1/20 0.44
MMP13 P45452 1/20 0.44
MMP1 P03956 1/20 0.43
MMP3 P08254 1/20 0.43
KMT2A Q03164 1/20 0.43
PPARG P37231 1/20 0.43
NPY1R P25929 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8938060 0.88 ITGB3 (0.57) ITGB3ITGA2BLTA4HLMNAALDH1A1
SCHEMBL829349 0.86 SLC7A5 (0.51) ITGB3ITGA2BLTA4H
SCHEMBL7688895 0.85 ITGB3 (0.57) ITGB3ITGA2BFOLH1LMNAACE
SCHEMBL7559199 0.83 ITGB3 (0.52) ITGB3ITGA2BLMNAALDH1A1MME
SCHEMBL1406153 0.81 CTSS (0.50)
SCHEMBL8477239 0.81 ITGB3 (0.62) ITGB3ITGA2BFOLH1LMNAACE
SCHEMBL9337698 0.81 ITGB3 (0.62) ITGB3ITGA2BFOLH1LMNAACE
SCHEMBL11183676 0.81 ITGB3 (0.62) ITGB3ITGA2BFOLH1LMNAACE
SCHEMBL8977599 0.80 ITGB3 (0.56) ITGB3ITGA2BFOLH1LMNAACE
SCHEMBL16909929 0.80 SLC7A5 (0.58) ITGB3ITGA2BFOLH1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020137124-A1 Process for the continuous production of dipeptide crystals in a membrane and hydro-cyclone reactor using a peptidase INSTITUTO SUPERIOR TECHNICO (PT) 2002-09-26 US disclosed
WO-2001088175-A1 PROCESS FOR THE CONTINUOUS PRODUCTION OF DIPEPTIDE CRYSTALS IN A MEMBRANE AND HYDRO-CYCLONE REACTOR USING A PEPTIDASE INSTITUTO SUPERIOR TÉCNICO (PT) 2001-11-22 WO disclosed
US-5508182-A PRODUCING AMPHIPHILIC COMPOUNDS, 1-MONOGLYCERIDES, SUGAR ETERS ON SOLID SUPPORTS USING A HYDROLASE SCHNEIDER MANFRED P (DE) 1996-04-16 US disclosed
WO-1992014830-A1 ENZYMATIC REVERSE HYDROLYSIS OF HYDROPHILIC SUBSTRATES - PREPARATION OF AMPHIPHILIC COMPOUNDS SCHNEIDER MANFRED P (DE) 1992-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137124-A1 Process for the continuous production of dipeptide crystals in a membrane and hydro-cyclone reactor using a peptidase LCT, PEPD, CPN1 ITGB3 4862/4885ITGA2B 4867/4885LTA4H 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.